Molecular Testing

You are here

Molecular Testing

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

Case Based Panel Discussion NSCLC – Does a Positive HER2 Mutation Effect Treatment Decisions?
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Molecular Testing
Case Based Panel Discussion Stage 3 NSCLC - Tumor Mutational Burden (TMB), and the Value in Testing
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Non Small Cell Lung Cancer, Molecular Testing
Case Based Panel Discussion - Stage 3 NSCLC Patient with PDL1 Score of 0, Is Immunotherapy Beneficial?
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Non Small Cell Lung Cancer, Immunotherapies, Molecular Testing
Case Based Panel Discussion - Unresectable NSCLC, Should Molecular Tests be Considered, and Would Outcome Effect Treatment Decisions?
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Non Small Cell Lung Cancer, Molecular Testing
,
,
,
,
Molecular Diagnostics Testing and Next Generation Sequencing
The Global Resource for Advancing Cancer Education (GRACE), presents Molecular Diagnostic Testing and Next Generation Sequencing in Lung Cancer webinar series.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Molecular Testing

Articles

Translation of Molecular Genetics in Lung Cancer into Treatment Decision
Christine M. Walko, Pharm.D., discusses how advancements in technology have improved the quality, cost and turnaround time for assessing genetic mutations in tumor tissue, and how this has helped to translate precision medicine into standard clinical practice.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Molecular Testing, General Lung Cancer
What is the Role of Molecular Marker Testing in the Adjuvant or Post-Op Setting?
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Molecular Testing, Adjuvant Therapy, Targeted Therapy
Access & Assistance for ALK+, ROS1 & EGFR Patients
Brendan Bietry of the Patient Advocate Foundation discusses the financial assistance programs available to lung cancer patients who receive targeted therapies.
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, Procedures & Treatments, Molecular Testing, Biopsy/Tissue Collection, Scans - PET-CT, etc.
Panel Q&A Session on Acquired Resistance with Drs. Riely & Horn
Dr. West moderates a question & answer session with Drs. Leora Horn and Greg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, Molecular Testing
Repeat Biopsies and Emerging Technologies for Plasma Sampling of Mutations Seen with Acquired Resistance
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, Procedures & Treatments, First-line treatment, Molecular Testing, Maintenance Therapy, Symptoms, Biopsy/Tissue Collection

Community Forum

Progression on Tarceva - T790m negative
Progression after 3 1/2 years on Tarceva. Tissue biopsy showed T790m negative. Any suggestions/experience on next steps? Onc suggesting I move to Afatinib or a Opdivo. PDL1 was tested and is <1%.
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Lung Cancer, General Lung Cancer, Targeted Therapies - EGFR, Targeted Therapy, Molecular Testing, Immunotherapies, Non Small Cell Lung Cancer